65,437 trials
Therapeutic Adherence and Compliance
Primary: TFV-diphosphate (TFV-DP) Drug Level — 1377.82; 1156.79 fentomole/punch — p=.014
Time · Patient Preference
Primary: Placement Time of Sealants Using Dryshield (DS) vs Cotton Rolls (CRI) — 164.88; 160.50; 164.56; 167.81 Seconds
Plaque Psoriasis
Primary: The Primary Outcome Measure Will be to Evaluate Change in Aberrant Inflammatory Profiles of Activated Blood Monocytes (Aberrant-monocyte Endotype Patients (AM-endotype)…
Clostridium Difficile Immunisation · Diphtheria · Diphtheria Immunisation
Primary: Number of Pregnant Women Reporting Related Serious Adverse Events (SAEs) and Unrelated SAEs — 0; 0; 20; 10 Participants
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Toxicities — 0 Participants
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Transcatheter Aortic Valve Implantation
Primary: Post Procedure Hospital Length of Stay — 4.8; 3.5 days
Erythropoietic Protoporphyria (EPP)
Primary: Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week…
Spondylitis, Ankylosing · Arthritis, Psoriatic
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 10; 18 Participants
Blastoid Variant Mantle Cell Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Follicular Lymphoma
Primary: Progression Free Survival Probability at 12-month Post HCT — 0.80 probability
Bone Metastasis · Cancer Pain
Primary: Change From Baseline in the Daily Average Pain Intensity Numerical Rating Score (NRS) in the Index Bone Metastasis Cancer Pain Site at Week 8 — -1.25; NA; NA; -2.03…
Head and Neck Cancer · Survivorship · Nutrition Aspect of Cancer
Primary: Number of Participants Meeting Patient-Caregiver Session and Care Plan Acceptability Criteria — 18; 18; 17; 15 participants
End-stage Renal Disease (ESRD)
Primary: Number of Participants With Major Bleeding (MB) and Clinically Relevant Non-Major Bleeding (CRNMB) — 3; 2; 3; 3 Participants
Osteoarthritis · Avascular Necrosis · Traumatic Arthritis
Primary: Rate of Patient Success at 24 Months. — 120 Participants
Neoplasms
Primary: Overall Survival — 8.2; 7.8 Months